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Abstract
Objectives
Research on the treatment of second-trimester miscarriages is scarce. We studied the out-
comes, and the factors associated with adverse events and need for hospital resources in
the medical treatment of second-trimester miscarriage.
Materials and methods
In these retrospective analyses we studied women treated for spontaneous fetal miscar-
riage with misoprostol-only (n = 24) or mifepristone and misoprostol (n = 177) in duration of
gestation 12+1–21+6. Primary outcomes were the risk factors for surgical evacuation and
excessive bleeding. Secondary outcomes were total misoprostol dose, time to expulsion
and the length of hospital stay.
Results
History of surgical evacuation of the uterus increased the risk of surgical evacuation (p =
0.027). Excessive bleeding was not associated with any of the studied variables. More miso-
prostol was needed when the duration of gestation exceeded 17+0 weeks (p = 0.036). In
multivariate analysis the time to fetal expulsion was shorter in women with history of 1–2
deliveries (hazard ratio [HR] 1.49, 95% confidence interval [CI]; 1.07–2.07),3 deliveries
(HR 1.63, 95% CI; 1.11–2.38) and with a two-day interval between mifepristone-misoprostol
administration (HR 1.71, 95% CI; 1.05–2.81). Patients with symptoms (i.e. uterine bleeding
or pain) at baseline had longer hospital stay (HR 0.66, 95% CI; 0.47–0.92).
Conclusions
The factors affecting the outcomes of medical treatment of second-trimester fetal miscar-
riage are similar to those of second-trimester induced abortion. Two-day interval between
mifepristone-misoprostol administration might decrease the time to fetal expulsion and the
need of hospital resources.
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Introduction
Miscarriage is a common event in a woman’s life. Approximately 20% of clinically recognized
pregnancies end in a miscarriage [1]. Most miscarriages occur before 12 weeks and it has been
estimated that only 2–3% of pregnancies end spontaneously in the second trimester [2]. Sec-
ond-trimester pregnancy loss has been defined as miscarriage diagnosed between the duration
of gestation of 12–24 weeks [2]. The Special Interest Group for early pregnancy in European
Society of Human Reproduction and Embryology (ESHRE) has made a consensus statement
to harmonize inconsistent terminology of pregnancy failure. According to the ESHRE state-
ment the term fetal miscarriage should be used in pregnancy loss 10 weeks of gestation with
a fetus measuring 33 mm on ultrasound [3]. According to the World Health Organization,
miscarriage is defined as the premature loss of a fetus at< 22+0 weeks of the pregnancy and
weighing < 500 g [4].
Medical management of miscarriage and induced abortion has become the gold standard
in clinical practice in several northern European countries. However, the treatment of second
trimester miscarriage has been addressed in only few research studies. In a recent systematic
review of medical treatments for incomplete miscarriage, no randomized trials focused specifi-
cally on the treatment of miscarriage beyond 13 week´s gestation were identified [5]. Thus
the clinical practice on the treatment of late miscarriages is mainly based on the knowledge
derived from studies on second trimester induced abortion. Still, miscarriage can be consid-
ered a pathophysiologically separate entity compared to induced abortion, in which potentially
viable fetus is expulsed with the use of medication. Women with miscarriage are a heteroge-
neous group, presenting with widely varying etiologies, such as infections, chromosomal
abnormalities of the mother and/or the fetus, antiphospholipid syndrome and congenital uter-
ine anomalies [2].
In a randomized study comparing the use of misoprostol and oxytocin in cases of both fetal
miscarriages and induced abortions in the second trimester women with miscarriage had a
shorter time to expulsion compared to women with induced abortion [6]. In randomized trials
[7–9] the use of the mifepristone-misoprostol combination decreased the time to fetal expul-
sion and increased the rate of successful uterine evacuation, compared to use of misoprostol
alone, in women with second trimester induced abortion [7–9]. In Finnish register-based
study the rate of surgical evacuation was 39% after second trimester medical induced abortion
including both mifepristone and misoprostol [10]. Moreover, in a randomized study compar-
ing the effects of one- and two-day dosing intervals between mifepristone and misoprostol the
rate of surgical evacuation was 31%. This risk was increased by a history of surgical evacuation,
fetal indications of induced abortion, age> 24 years and a two-day dosing interval between
mifepristone and misoprostol [11]. In contrast, in previous studies on medical induced abor-
tion shorter time to fetal expulsion has been associated with parity and lower gestational age
[6, 10].
We evaluated the outcomes of spontaneous second trimester miscarriages treated with
misoprostol-only or with a combination of mifepristone and misoprostol. The primary out-
come was to identify the factors associated with adverse outcomes (the need of surgical evacua-
tion and excessive bleeding). The secondary outcome was to investigate the need of hospital
resources (misoprostol dose, time to fetal expulsion and length of hospital stay).
Materials and methods
The study was conducted between 1st December 2008 and 31st December 2011 in two Finnish
tertiary care hospitals; the Departments of Obstetrics and Gynecology at the Helsinki and
Oulu University Hospitals. The setting was retrospective. The data was collected by three
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authors (MM, RJ, AH) and fully deindetified before accessed and analysed by MN. A system-
atic search was conducted in both hospitals wherein data were collected on all patients treated
with ICD10-codes O02.X or O03.X. Of these women, those with a spontaneous fetal miscar-
riage (a non-viable fetus visible in the ultrasound examination) and duration of pregnancy
between 12+1–21+6 gestational weeks were included. Multiple pregnancies were excluded. In
cases with several miscarriages per woman during the study period, only the first miscarriage
was included. Three patients were excluded as they were treated with intravenous oxytocin
only. One patient was excluded because of missing information on the treatment at the ward
(number of misoprostol doses and time to fetal expulsion). Three patients experienced fetal
expulsion following mifepristone-only and were included in the mifepristone-misoprostol
group. Using these criteria we identified altogether 150 women in the Helsinki University Hos-
pital and 51 women in the Oulu University Hospital.
We collected data from individual patient files on the age of the woman at the time of diag-
nosis, previous pregnancies, vaginal deliveries, miscarriages, induced abortions and surgical
evacuations. The symptoms (abdominal pain, cramps and bleeding) experienced at the time of
diagnosis were also collected. According to Finnish practice, all fetuses are scanned using
ultrasonography to confirm the miscarriage. However, the duration of pregnancy was calcu-
lated from the last menstrual period as we found it clinically more relevant than ultrasound
definition of the fetus although some discrepancy may occur. We assumed that in cases of
intrauterine death the size of the fetus may not the match the duration of gestation due to fetal
growth restriction or fetal decay, and thus it is not any more accurate method. Data were also
collected on the treatment, specifically on mifepristone administration and the interval
between the administration of the mifepristone dose and hospital admittance, total dose and
number of misoprostol doses, volume of bleeding (as estimated by the staff on the ward and in
the operation room) and time to fetal expulsion (calculated from the first misoprostol dose)
and length of the hospital stay (overnight treatment from the day when the woman attended
the ward to receive misoprostol). Bleeding exceeding 1000 ml was considered excessive.
Most patients (n = 177) received 200 mg of mifepristone orally at the first outpatient visit.
Thereafter, they were admitted to the ward 0–72 hours later and the first misoprostol dose was
administered vaginally. The initial dose of misoprostol was 400–800 μg. Repeat vaginal doses
(400 μg) were given at three-hour intervals until fetal expulsion was achieved. However, 24
patients received repeated doses of misoprostol-only without pretreatment with mifepristone.
The Department of Obstetrics and Gynecology, and Pediatrics of the Hospital District of
Helsinki and Uusimaa granted a permission for the study (§17/24.05.2011). According to
Finnish law, a medical research ethics committee statement is not required in a clinical study
where the clinical information has been obtained through a retrospective audit and the
patients have not been contacted for the purposes of performing the study.
Statistical analyses
Statistical analyses were performed using IBM SPSS1 Statistics 22 software. The chi-square
test was used for a comparison of the categorical variables. The Mann-Whitney U-test or Krus-
kal-Wallis tests were employed for analysis of the continuous variables. Cox´s regression was
performed to evaluate the time to successful events, i.e. misoprostol dose, time to fetal expul-
sion and length of hospital stay. Univariate analyses were performed initially. Data indicating
statistical significance were further evaluated using multivariate analysis. Multicollinearity was
tested by using a linear regression test. A variance inflation factor (VIF) >2.5 was interpreted
as multicollinearity between the variables. Accordingly, the relevant data were discarded from
the multivariate analysis. The level of statistical significance was set at P< 0.05.
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Results
201 women with second trimester miscarriage met the inclusion criteria. Their mean age (±
standard deviation [SD]) was 32.4 (±5.5) years. The current pregnancy was the first for 34
women (17%), 109 women had had 2–4 previous pregnancies (54%) and 58 women had
had 5 previous pregnancies (29%). Of these women 177 (88%) were treated with the combi-
nation of mifepristone and misoprostol. The remaining women (n = 24) were treated with
misoprostol-only. Mean duration of gestation was 117.1 days when defined by the last men-
strual period and 103.4 days according to the size of the fetus in the ultrasonographic examina-
tion at the time of diagnosis. The results did not alter significantly, when calculated according
to the ultrasonographic dating of gestation.
The primary outcomes (surgical evacuation during the first hospital stay and bleeding
exceeding 1000 ml) were analysed according to the background characteristics and the use of
mifepristone (Table 1). Surgical evacuation of the uterus because of bleeding and/or retained
products of conception was performed during the first hospital stay in 51 patients (25%) and
within eight weeks in 65 (32%). In all cases fetus had been expulsed before surgical evacuation.
Bleeding was estimated to be excessive in 54 women (27%). A history of previous surgical evac-
uation of the uterus (p = 0.027) was associated with the need for surgical evacuation. None of
the parameters studied were associated with excessive bleeding.
We analysed the need for hospital resources according to the different parameters; total
misoprostol dose, time to fetal expulsion and length of hospital stay (Table 2). The total dose of
misoprostol needed was significantly higher when the duration of gestation was 17+0 weeks
(p = 0.036). Time to expulsion was shorter in women with a history of pregnancy (p = 0.010)
and delivery (p = 0.004) with a greater interval between the administration of mifepristone and
misoprostol (p = 0.016) and when the duration of pregnancy was< 17+0 weeks (p = 0.023).
Length of hospital stay was shorter in women with a history of delivery (p = 0.010), in women
who received mifepristone (p = 0.003) and in those in for whom the dosing interval between the
administration of mifepristone and misoprostol was greater (p = 0.003). Women with symp-
toms at baseline experienced a longer hospital stay than asymptomatic women (p< 0.001). A
longer duration of gestation was associated with a longer hospital stay (p = 0.006).
The association between mifepristone administration, and the absence or presence of
symptoms at the time of diagnosis was also analyzed. Mifepristone was used less frequently in
symptomatic than in asymptomatic women (71.9% vs. 92.9%, p = 0.001). In addition, the
mifepristone-misoprostol interval was shorter in symptomatic women. The dosing interval
was 0, 1 or 2 days in 11 (7.8%), 80 (56.7%) and 50 (35.3%) asymptomatic women and 14
(23.3%), 36 (60.0%) and 10 (16.7%) symptomatic women, respectively (p = 0.001).
Cox´s regression analysis was carried out to examine, which parameters were associated
with the total misoprostol dose, time to fetal expulsion and the length of hospital stay
(Table 3). None of the variables had a significant association with the misoprostol dose in uni-
variate analysis. In contrast, univariate analysis revealed a significant association between the
time to expulsion and the number of previous pregnancies and vaginal deliveries, the mifepris-
tone-misoprostol interval and the duration of gestation. Number of previous pregnancies and
deliveries showed multicollinearity. Thus, we chose to discard the number of previous preg-
nancies from the multivariate analysis. Of the three parameters included in the multivariate
model, a history of 1–2 (hazard ratio [HR] 1.49, 95% confidence interval [CI];1.07–2.07)
or 3 vaginal deliveries (HR 1.63, 95% CI; 1.11–2.38) and a two-day dosing interval between
mifepristone and misoprostol (HR 1.71, 95% CI; 1.05–2.81) were associated with a shorter
time to expulsion. In univariate analysis symptoms and mifepristone interval were associated
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with the length of hospital stay, and were entered to multivariate model, in which women with
symptoms had longer duration of hospital stay (HR 0.66, 95% CI; 0.47–0.92).
Discussion
History of surgical evacuation of the uterus was the only parameter associated with the risk of
further surgical evacuation following medical treatment of fetal miscarriage. There might be
Table 1. Patient characteristics, use of mifepristone and the primary outcomes.
Surgical evacuation Exessive bleeding (estimated > 1000 ml)
(n,%) p (n,%) p
Age, years (n)
less than 25 (17) 1 (5.9) 0.186 1 (5.9) 0.322
25–29 (38) 9 (23.7) 10 (26.3)
30–34 (70) 16 (22.9) 19 (27.1)
35–39 (57) 18 (31.6) 18 (31.6)
40 or more (19) 7 (36.8) 6 (31.6)
Previous pregnancies (n)
1 (34) 7 (20.6) 0.080 7 (20.6) 0.153
2 to 4 (109) 23 (21.1) 26 (23.9)
5 or more (58) 21 (36.2) 21 (36.2)
Previous vaginal deliveries* (n)
0 (64) 14 (21.9) 0.701 14 (21.9) 0.423
1 to 2 (86) 24 (27.9) 27 (31.4)
3 or more (50) 13 (26.0) 13 (26.0)
Previous miscarriages (n)
0 (131) 33 (25.2) 0.502 35 (26.7) 0.593
1 to 2 (57) 13 (22.8) 14 (24.6)
3 or more (13) 5 (38.5) 5 (38.5)
Previous induced abortions (n)
No (177) 43 (24.3) 0.340 46 (26.0) 0.446
Yes (24) 8 (33.3) 8 (33.3)
Previous surgical evacuations of the uterus (n)
No (163) 36 (22.1) 0.027 41 (25.2) 0.257
Yes (38) 15 (39.5) 13 (34.2)
Duration of gestation, weeks (n)
12+1–16+6 (112) 29 (25.9) 0.849 29 (25.9) 0.727
17+0–21+6 (89) 22 (24.7) 25 (28.1)
Symptoms at the baseline (n)
No (141) 37 (26.2) 0.665 37 (26.2) 0.759
Yes (60) 14 (23.3) 17 (28.3)
Mifepristone administration
No (24) 6 (25.0) 0.964 8 (33.3) 0.446
Yes (177) 45 (25.4) 46 (26.0)
Mifepristone-misoprostol interval, days (n)
0 (25) 5 (20.0) 0.799 7 (28.0) 0.560
1(116) 30 (25.9) 28 (24.1)
2 (60) 16 (26.7) 19 (31.7)
* 1 missing value
https://doi.org/10.1371/journal.pone.0182198.t001
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some underlying explanations, such as insufficient maturing of the cervix or lower uterine
contractility, which unfortunately cannot be further studied in the present study setting.
In contrast, no risk factors for excessive bleeding could be identified. When the duration of
gestation exceeded 17+0 weeks, a higher total dose of misoprostol was needed. Time to fetal
expulsion was shorter in parous women and when the mifepristone-misoprostol interval was
two days, compared to a zero-day interval. The length of hospital stay was longer in symptom-
atic women than in asymptomatic women. We speculate that this is due to the cautious pre-
treatment of symptomatic women with mifepristone. The symptoms experienced could be
interpreted as signs of spontaneous onset of miscarriage and led to the non-use of mifepristone
Table 2. Need for hospital resources (misoprostol dose, time to expulsion and the length of hospital stay).
Misoprostol dose mg, mean
(median, SD)
p Time to expulsion* (minutes), mean
(median, SD)
p Length of hospital stay (days),
mean (median, SD)
p
Age, years
(N)
less than 25
(17)
1.29 (1.20, 0.63) 0.861 489.4 (360.0, 373.5) 0.422 1.53 (1.00, 0.62) 0.614
25–29 (38) 1.13 (1.20, 0.39) 398.6 (357.5, 200.2) 1.55 (1.00, 1.22)
30–34 (70) 1.11 (1.20, 0.40) 390.0 (350.0, 216.7) 1.79 (1.00, 1.22)
35–39 (57) 1.11 (1.20, 0.38) 363.4 (320.0, 199.7) 1.79 (2.00, 1.16)
40 or more
(19)
1.27 (0.80, 1.03) 330.3 (330.0, 252.9) 1.79 (1.00, 1.40)
Previous pregnancies (N)
1 (34) 1.22 (1.20, 0.46) 0.110 475.1 (440.0, 256.3) 0.010 1.97 (2.00, 1.19) 0.076
2 to 4 (109) 1.12 (0.80, 0.56) 381.4 (330.0, 228.0) 1.69 (1.00, 1.30)
5 or more
(58)
1.15 (1.20, 0.39) 345.0 (310.0, 206.1) 1.64 (1.50, 0.87)
Previous vaginal deliveries* (N)
0 (64) 1.22 (1.20, 0.63) 0.198 444.6 (402.5, 239.4) 0.004 2.00 (2.00, 1.30) 0.010
1 to 2 (86) 1.08 (0.80, 0.43) 374.0 (330.0, 227.0) 1.61 (1.00, 1.28)
3 or more
(50)
1.16 (1.20, 0.40) 335.2 (270.0, 213.2) 1.58 (1.00, 0.70)
Symptoms at the baseline (N)
No (141) 1.10 (1.20, 0.35) 0.445 370.4 (330.0, 193.6) 0.313 1.47 (1.00, 0.72) <0.001
Yes (60) 1.25 (1.20, 0.75) 430.0 (345.0, 301.5) 2.32 (2.00, 1.71)
Mifepristone administration
No (24) 1.23 (1.20, 0.67) 0.663 434.5 (375.0, 339.0) 0.602 2.46 (2.00, 1.64) 0.003
Yes (177) 1.13 (1.20, 0.47) 380.9 (330.0, 211.4) 1.62 (1.00, 1.07)
Mifepristone-misoprostol interval, days (N)
0 (25) 1.25 (1.20, 0.66) 0.281 431.8 (362.5, 340.0) 0.016 2.40 (2.00, 1.61) 0.003
1(116) 1.17 (1.20, 0.51) 410.7 (357.5, 214.2) 1.74 (1.00, 1.23)
2 (60) 1.05 (0.80, 0.37) 324.4 (290.0, 194.9) 1.40 (1.00, 0.62)
Duration of gestation, weeks (N)
12+1–16+6
(113)
1.09 (1.00, 0.50) 0.036 357.4 (320.0, 211.2) 0.023 1.55 (1.00, 1.02) 0.006
17+0–21+6
(92)
1.21 (1.20, 0.49) 423.9 (370.0, 247.8) 1.94 (2.00, 1.32)
SD = standard deviation
Mg = milligrams
*Time from the first misoprostol dose to expulsion of the fetus
https://doi.org/10.1371/journal.pone.0182198.t002
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or to the use of a short mifepristone-misoprostol interval. In fact, symptomatic women
received mifepristone less frequently, and the dosing interval between mifepristone and miso-
prostol administration was shorter. Thus, these women might also benefit from pretreatment
with mifepristone.
As the existing data on the treatment of second-trimester miscarriages are scarce, and
national or international guidelines are lacking, we found the present analysis important. In
order to collect sufficient data, the patents were collected from two large Finnish tertiary care
hospitals. The retrospective nature of the study is a shortcoming. Second-trimester miscar-
riages are a rare, and prospective studies would need to be conducted over a greater length of
time and involve high patient volumes.
Given the rarity of late miscarriage, the different treatment protocols for second trimester
fetal miscarriage have not been assessed in prospective trials. A systematic review and meta-
analyses aiming to establish recommendation for post-abortion care in second trimester
showed that pretreatment with mifepristone was associated with shorter expulsion of the fetus.
However, the articles included were heterogeneous including both induced abortions (legal
or illegal) and spontaneous pregnancy failures (fetal demise, ruptured membranes and
Table 3. Cox´s regression of time to expulsion and length of hospital stay (univariate and multivariate analysis).
Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Time to expulsion (minutes)
Previous pregnancies (N) *
1 (34) 1
2 to 4 (109) 1.43 (0.97–2.11) 0.069
5 or more (58) 1.68 (1.09–2.51) 0.018
Previous vaginal deliveries (N)
0 (65) 1 1
1 or 2 (89) 1.38(0.99–1.92) 0.053 1.49 (1.07–2.07) 0.019
3 or more (50) 1.63 (1.12–2.38) 0.011 1.63 (1.11–2.38) 0.012
Mifepristone-misoprostol interval, days (N)
0 (25) 1 1
1 (116) 1.15 (0.73–1.81) 0.542 1.19 (0.76–1.88) 0.446
2 (60) 1.66 (1.02–2.70) 0.041 1.71 (1.05–2.81) 0.033
Duration of gestation, weeks (N)
12+1–16+6 (113) 1 1
17+0–21+6 (92) 0.75 (0.56–0.99) 0.044 0.76 (0.57–1.01) 0.057
Length of hospital stay (days)
Symptoms at the baseline (N)
No (141) 1 1
Yes (60) 0.62 (0.45–0.85) 0.003 0.66 (0.47–0.92) 0.015
Mifepristone-misoprostol interval, days (N)
0 (25) 1 1
1(116) 1.35 (0.87–2.09) 0.176 1.22 (0.79–1.91) 0.371
2 (60) 1.68(1.04–2.70) 0.034 1.41 (0.86–2.31) 0.178
*Discarded from multivariate analysis due to multicollinearity with vaginal deliveries
1 = reference group
HR = Hazard Ratio
CI = Confidence Interval
https://doi.org/10.1371/journal.pone.0182198.t003
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incomplete abortion) [12]. The treatment protocol used for spontaneous fetal miscarriages in
Finland is in line with recent WHO recommendations for medical termination of pregnancy
after 12 weeks of gestation [13]. However, in the absence of randomized clinical trials or clini-
cal guidelines not all patients receive similar care. For example, in the presence of clinical
symptoms suggestive of spontaneous abortion the clinician may decide not to administer
mifepristone prior to misoprostol. This was seen in 12% of cases in the present study.
Generally, factors affecting the outcome of second-trimester spontaneous fetal miscarriage
treated medically were found to be similar to those in second-trimester medical induced abor-
tion. In a prospective randomized trial the history of surgical evacuation of the uterus was also
identified as a risk factor for surgical evacuation in second-trimester medical induced abortion
[11]. Nulliparous women were likely to experience a longer induction-to-abortion interval
than uni- or multiparous women in second-trimester medical induced abortion in another ret-
rospective study [14]. Unlike the findings of the study on medical induced abortion by Abbas
et al. (2016), the mifepristone-misoprostol interval was not associated with the misoprostol
dose in our study [15]. However, the time to fetal expulsion was shorter in relation to increased
mifepristone-misoprostol interval and also in women with a history of vaginal delivery. This
has also been observed in medical second-trimester induced abortion [15]. The two-day inter-
val between mifepristone and misoprostol has been shown to associate with shorter time to
expulsion and also a lower incidence of surgical evacuation, compared to one-day interval in
second-trimester medical induced abortion [16]. According to other studies, administration
interval of 36–48 hours interval was considered preferable in second-trimester induced abor-
tion [17].
Several studies have provided convincing evidence on the advantages of combined mifep-
ristone-misoprostol protocol, instead misoprostol-only in second-trimester induced abortion
[7–9,18]. In cases of spontaneous fetal miscarriage, the practice is not clear. It seems that the
results of studies on second-trimester induced abortion can also be generalized to fetal miscar-
riages. As guidelines are lacking, treatment protocols used in second trimester medical
induced abortion can also be applied to second-trimester missed miscarriage. Based on our
results, the use of mifepristone, and especially a longer mifepristone-misoprostol interval
might reduce the time to fetal expulsion. Multicenter studies using a prospective randomized
setting are needed to confirm these findings.
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